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Abstract
Background—There is a worldwide need for a pediatric HIV-1 diagnostic test that has a high
diagnostic accuracy, is technically simple and cost efficient. The Up24 HIV-1 assay, which requires
both the HIV-1 p24 ELISA and the ELAST signal amplification kit, has previously been shown to
be a robust tool to diagnose pediatric HIV-1 from dried whole blood spots (DBS) (Cachafeiro et al.,
JCM 2009;47:459–6213). In order to make the assay more accessible to a resource-limited clinical
setting, we eliminated the ELAST system, which simplified the Up24 assay, reduced its cost, and
tested the accuracy of the modified assay in a rural Malawian hospital.
Objectives—In this proof of concept study, we tested the ability of a simplified Up24 antigen assay,
without ELAST, to detect HIV-1 on DBS obtained via heel prick from 6-week-old Malawian infants.
Study design—A case–control study of DBS collected from 113 HIV-infected and 109 HIV-
negative infants, using the HIV-1 DNA PCR assay as the reference standard.
Results—The simplified HIV-1 Up24 assay had a sensitivity and specificity of 84% and 98%,
respectively. When HIV-1 prevalence is 15%, the positive- and negative-predictive values are 89%
and 97%, respectively.
Conclusion—The simplified Up24 assay has a good positive- and a robust negative-predictive
values, is easier to perform and has a reduced cost compared to both HIV DNA PCR and Up24 assays.
With additional testing, the simplified Up24 assay has the potential to increase global access to
pediatric HIV-1 diagnostics.
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1. Background
Despite the evidence that timely antiretroviral treatment (ART) in HIV-infected infants reduced
death by approximately 75%,1 only 35% of the HIV-infected children in sub-Saharan Africa
(SSA) were receiving ART.2 The lack of affordable, accessible and accurate HIV-1 infant
diagnostic tests is one of the major bottlenecks limiting timely access to ART among children
in SSA. In Malawi, it is estimated that 85,488 HIV-infected mothers deliver annually,3 but in
2009, only three public hospitals located in urban districts in Malawi had capacity to perform
HIV DNA PCR. However, in an attempt to increase coverage of infant HIV testing, the Early
Infant Diagnosis (EID) Programme collects dry blood samples for centralized PCR testing
from 41 of the 425 health facilities delivering prevention of HIV mother-to-child transmission
(PMTCT) services.3,4 One of the EID testing facilities is based at Queen Elizabeth Central
Hospital (QECH) located in the city of Blantyre (population ~660,0005); QECH is the only
public health facility in the southern region of Malawi (population ~5.9 million3) with the
capacity to conduct HIV DNA PCR. In 2009, QECH performed 8642 tests of which 2297 were
from Blantyre city (Hannania Moyo, EID Senior Laboratory Technician, QECH, personal
communication). Thus, it is estimated that that only ~11% of the Malawian children have ready
access to HIV DNA PCR. This system poses logistical problems and ultimately limits coverage
of ART in children.
Several published studies have demonstrated the ability of HIV-1 p24 antigen detection assays
to diagnose pediatric HIV-infection in plasma6–12 and dried blood spots from venous blood.
13–16 Importantly, the Up24 assay has been validated against HIV-1 subtype C, which
comprises >95% of all HIV-infections in Malawi7,11,12,15–19 and it can be easily adapted to a
resource-limited setting.20 Up24 assays contain two modules, a p24 ELISA and ELAST
(ELISA signal amplification kit), and two reagents comprise the ELAST kit: the Biotynil
Tyramide and the ELAST HRP, and collectively, the ELAST reagents increase the sensitivity
of the p24 ELISA. Before using the ELAST kit, the Biotynil Tyramide needs a single step
dilution, and the ELAST HRP needs a two-step serial dilution, which must be experimentally
determined for each lot. As a result, in addition to increasing the cost per test of the Up24 assay,
the ELAST module adds technical complexity, labor time, and it increases assay variability.
2. Objective
In this proof of concept study, we tested the ability of a simplified Up24 antigen assay, without
ELAST, to detect HIV-1 on DBS obtained via heel prick from 6-week-old Malawian infants.
3. Study design
IRB approval was obtained from the Malawi College of Medicine Research Ethics Committee
and the Ohio State University. Additional permission was obtained from the Malawi Ministry
of Health to use archived, de-identified DBS samples from infants who attended the Thyolo
District Hospital. A priori sample size calculations indicated that 136 HIV-infected and 118
HIV-negative samples would give an 80% power at the 0.05 significance level to detect
differences from the HIV-1 DNA PCR test when the sensitivity or specificity of the HIV-1
Up24 test is below 90%. Infant DBS samples from the Thyolo District Hospital are currently
tested for HIV-1 at Queen Elizabeth Central Hospital (referral hospital in Southern Malawi)
with the Roche Amplicor HIV-1 DNA PCR assay when the infant is 6 and 10 weeks old, and
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again 6 weeks after breastfeeding has stopped. The DBS cards were stored in ziploc bags
containing dessicant and a humidity detector card, and the samples were excluded if the
humidity detector card showed abnormalities. DBS samples from HIV-exposed 6-week-old
infants who had an unequivocal negative or positive DNA PCR result were selected. Three 6
mm punches from a single DBS were collected and transported to Thyolo District Hospital for
HIV-1 Up24 antigen testing by a Malawian laboratory technician who was masked to the HIV-1
DNA PCR results. Alliance® HIV-I p24 ELISA kits (Perkin Elmer) were purchased from
Separation Scientific SA (Honeydew, South Africa) and Up24 assays were performed as
reported by Cachafeiro et al.,13 with the modifications described in Table 1. When the
simplified Up24 ELISA and HIV DNA PCR were discordant at any of the cutoff values, a third
DBS was sent to the UNC Core Retrovirology lab for an additional HIV-1 DNA PCR assay
(Roche HIV-1 DNA PCR v1.5). The tiebreaker results from UNC lab were considered the true
HIV-1 status. Sensitivity, specificity, and likelihood ratios22 were determined from
contingency tables and positive- and negative-predictive values (PPV and NPV, respectively)
for each proposed cutoff were calculated according to the following equations:
where “sen” equals assay sensitivity, “spec” equals assay specificity, and “p” equals the
theoretical prevalence of the HIV-1 in the pediatric population.
4. Results
A total of 222 DBS samples from 113 HIV-infected and 109 HIV-negative infants were assayed
with the simplified HIV-1 p24 ELISA. The modifications listed in Table 1 were implemented
to compensate for the decreased sensitivity of the Up24 assay in the absence of ELAST
amplification step. In order to optimize the sensitivity and specificity of the simplified Up24
assay, several assay cutoffs were evaluated, including the following: the average of the negative
controls (NC) multiplied by two (2NC); NC plus 0.05 OD units (NC + 0.05); or NC + 2 standard
deviations (SD), NC + 3SD, or NC + 5SD. The data in Table 2A indicate that NC + 3SD had
the highest sensitivity and lowest specificity, while NC + 5SD had the highest specificity, an
intermediate sensitivity, and the highest positive likelihood ratio (Table 2B).
In order to explore the ability of the simplified Up24 assay to correctly diagnose pediatric
HIV-1 infection, we calculated the positive- and negative-predictive values for the five p24
assay cutoff-definitions over a plausible range of HIV-1 prevalence values (1–25%). Fig. 1
(top) shows that NC + 5SD had the most robust PPV over the entire prevalence range, with a
PPV of 89% at 15% HIV-prevalence. Fig. 1 (bottom) shows that all cutoff values had robust
NPVs, with NC + 5SD falling just slightly below the best cutoff values, with a NPV of 97%
at 15% HIV-prevalence.
5. Discussion
This study was done in a setting where overall rate of HIV-1 mother-to-child transmission
(MTCT) without any preventive intervention was previously estimated at approximately 28%.
23,24 With the roll-out of prevention of MTCT programs, the MTCT prevalence is likely to
have decreased to approximately 15%.25,26 Using the NC + 5SD cutoff, the PPV was between
84% and 89% at a theoretical HIV-1 prevalence of 10–15%; these data, in combination with
the high positive likelihood ratio (45.8), demonstrate that the simplified Up24 antigen detection
assay may be acceptable in resource-limited settings. However, a confirmatory test may still
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be required before starting HIV-infected infants on ART, especially if the estimated HIV-1
prevalence falls below 10%. The high NPV (>96%) at a pediatric HIV-1 prevalence of less
than 15% and the low negative likelihood ratio (0.16) demonstrates that a negative result is
very good at excluding infant HIV-infection. This means one can confidently use this test to
exclude infants who do not need confirmatory HIV-1 tests.
Our study had several limitations. First, we did not assess the diagnostic accuracy and PPV/
NPV of the simplified HIV-1 Up24 antigen assay in different hospital settings, which was
beyond the objectives of the study. Thus, before it could be considered for widespread use, the
simplified Up24 assay should be piloted in several district hospitals. Second, we included only
DBS samples with strongly negative or positive HIV-1 DNA PCR results, which may not
reflect a real-life situation, and the simplified Up24 assay should be explored on a set of
randomly selected DBS samples.
In summary, although the simplified HIV-1 Up24 antigen detection assay is less sensitive than
other HIV-1 diagnostics, this shortcoming is leveraged by the numerous advantages of the
simplified p24 antigen assay, which include the following: less expensive test costs (in Malawi,
the p24 assay described above is at least two- to three-fold cheaper per test), simpler technology
and equipment required for the assays, and the potential to decentralize the assay. Assay
decentralization would in turn reduce the costs associated with transporting the samples to the
central laboratory, reduce the logistical burden of delivering the results from the laboratory
back to the hospital, and most importantly, reduce the time between sample acquisition and
HIV-1 diagnosis.
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Variation in positive-predictive value (PPV, top panel) and negative-predictive value (NPV,
bottom panel) of the HIV-1 p24 antigen detection assay over a theoretical range of pediatric
HIV-1 prevalence values. PPV and NPV were calculated according to the formulas listed in
the text. NC: average of negative controls; SD: standard deviation.
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Table 1
Differences in assay conditions between this publication and Cachafeiro et al., JCM (2009). DBS: dried blood
spot; SDS: sodium dodecyl sulfate; HRP: horse radish peroxidase; ELAST: ELISA amplification system.
Characteristic Cachafeiro et al., JCM
(2009)13
This publication
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